drugset / Trial / NCT00383188

An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis

NCT00383188

Phase 2 Completed 305 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Investigating the safety and tolerability of a p38 inhibitor as monotherapy in subjects who have failed at least 1 DMARD.

Timeline

Start
2006-12-15
Primary completion
2008-07-01
Completion
2008-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject PH-797804 Small molecule 0.5 mg Oral
Subject PH-797804 Small molecule 3 mg Oral
Subject PH-797804 Small molecule 6 mg Oral
Subject PH-797804 Small molecule 10 mg Oral

Indications